Subcutaneous Drug Delivery Devices Market By Device Type (Conventional Syringes, Insulin Pens, GLP-1 Pen Injectors, Connected Pens, Prefilled Syringes, Autoinjectors, Wearable On-Body Injectors, Insulin Pumps, Automated Insulin Delivery Systems); By Delivery Format (Manual Injection Devices, Pen-Based Delivery Devices, Prefilled Delivery Systems, Wearable Large-Volume Delivery Devices, Connected and Digitally Enabled Delivery Devices); By Therapeutic Application (Diabetes, Obesity and Weight Management, Autoimmune and Inflammatory Diseases, Oncology, Neurology, Rare Diseases, Other Chronic Conditions); By Drug Type (Insulin, GLP-1 Receptor Agonists, Monoclonal Antibodies, Hormonal Therapies, Vaccines, Other Biologics and Specialty Drugs); By Volume Capacity (Small-Volume Delivery Devices, Medium-Volume Delivery Devices, Large-Volume Subcutaneous Delivery Devices); By End User (Home Care Settings, Hospitals and Clinics, Specialty and Ambulatory Care Centers, Pharmaceutical and Biotechnology Companies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Subcutaneous Drug Delivery Devices Market: GLP-1 Pens, Biologic Self-Administration, and Large-Volume Wearables Shift Value Beyond Conventional Syringes

The Global Subcutaneous Drug Delivery Devices Market was valued at USD 34.15 billion in 2025 and is projected to reach USD 55.67 billion by 2032, expanding at a CAGR of 7.23%, according to Strategic Market Research.

 

The Subcutaneous Drug Delivery Devices Market is undergoing a decisive structural shift. Conventional insulin syringes and basic pen systems no longer determine market leadership. Growth is being driven by the expansion of GLP-1 therapies and the acceleration of biologic self-administration. Prefilled syringes, autoinjectors, and on-body delivery systems are redefining treatment delivery standards. Large-volume wearable platforms and connected pen technologies are now central to improving adherence and enabling care outside clinical settings.

 

The demand base for subcutaneous delivery is broad, driven by chronic disease categories where frequent and long-term administration is clinically required. Diabetes represents the largest-volume application area. WHO estimates that 830 million people were living with diabetes globally in 2022, compared with 200 million in 1990, while more than half of affected individuals were not receiving diabetes medication in 2022. In the United States, CDC estimates that 40.1 million people had diagnosed or undiagnosed diabetes in 2023, representing 12.0% of the population. This substantial patient base continues to support demand for insulin pens, syringes, pen needles, insulin pumps, connected delivery devices, and associated consumables.

 

The market is also being influenced by the growing prevalence of obesity and expansion of biologic therapies. WHO-linked data show that more than 1 billion people were living with obesity in 2022, while GLP-1 drugs have made injectable weight management a mainstream pharmaceutical category. For device suppliers, this creates demand not just for drug filling capacity but also for precise, user-friendly, high-volume manufacturing of pens, cartridges, autoinjectors, and prefilled systems.

 

Diabetes and GLP-1 Therapy Define the Volume Layer

Diabetes remains the most durable device-use base because insulin therapy requires repeat, long-term subcutaneous administration. NIDDK states that most people taking insulin use a needle and syringe, insulin pen, or insulin pump, while inhalers and jet injectors are less common. ADA’s 2026 Standards of Care also recognize insulin delivery technology, including syringes, pens, connected pens, and insulin delivery systems, keeping the core device categories clinically embedded rather than optional.

Type 1 diabetes represents a smaller but highly device-dependent patient population. A 2025 global analysis estimated 9.50 million people living with type 1 diabetes, including 1.85 million under age 20. This matters commercially because type 1 diabetes requires lifelong exogenous insulin delivery, supporting continued demand for pens, pumps, smart pens, automated insulin delivery systems, and related disposable components.

India highlights the continued importance of emerging markets in expanding access to cost-effective subcutaneous delivery solutions. According to the ICMR–INDIAB study, approximately 101 million individuals were living with diabetes and 136 million with prediabetes in India in 2021. This large patient base supports sustained demand for insulin syringes, pens, pen needles, and emerging GLP-1 injectable therapies; however, affordability and healthcare access will remain key factors influencing device adoption.

GLP-1 therapies are increasingly influencing manufacturing priorities across the injectable drug delivery landscape. Reports from Reuters indicate that Novo Nordisk is gradually reducing human insulin pen production while expanding capacity for obesity and diabetes injectables, including Wegovy and Ozempic. This shift reflects a broader change in industry priorities, where manufacturing capacity for advanced injectable therapies is becoming strategically important as GLP-1 products compete with established insulin delivery requirements.

 

Prefilled Syringes and Autoinjectors Are Moving Self-Administration Upstream

Prefilled syringes and autoinjectors are gaining share because they reduce preparation steps, support home use, and lower administration burden. FDA classifies prefilled syringes, autoinjectors, pumps, and prefilled biologic delivery systems as combination product types, confirming that these devices sit inside regulated drug-device commercialization rather than accessory-only supply.

Regulatory trends also demonstrate the established role of advanced delivery formats in biologic-device combination products. A 2024 review of FDA-approved biologic-device combinations reported that all 16 insulin products incorporated pen injector systems, while all 19 vaccine products utilized prefilled syringes. These findings highlight the regulatory acceptance and clinical validation of pens and prefilled syringes as reliable platforms for biologic and injectable therapies.

Patient preference is further accelerating adoption of autoinjectors in chronic self-administered biologic treatment. In a randomized crossover study involving patients with moderate-to-severe ulcerative colitis receiving golimumab, 76.9% preferred the autoinjector immediately following administration, with preference remaining at 71.4% after two weeks. Autoinjectors also demonstrated higher usability ratings, with 94.5% of patients considering them easy or extremely easy to use compared with 73.6% for prefilled syringes.

This transition is reshaping supplier strategies across the drug delivery ecosystem. Device manufacturers are increasingly moving beyond basic containment solutions toward integrated delivery platforms designed to improve adherence, reduce training requirements, minimize injection-related concerns, and enable reliable long-term self-administration in home-based care settings.

 

Biologics Are Creating the Value Shift from Small-Volume to Large-Volume Devices

Biologics represent a major value driver for subcutaneous delivery beyond diabetes. Oncology, immunology, rare diseases, neurology, and autoimmune disorders are increasingly adopting subcutaneous administration where formulation characteristics and therapeutic requirements support its use. IARC/GLOBOCAN 2022 estimated nearly 20 million new cancer cases and 9.7 million cancer deaths globally, while WHO projects cancer incidence could exceed 35 million cases by 2050. This expanding therapeutic burden creates significant opportunity for subcutaneous biologics to reduce dependence on infusion-center administration when drug formulation and delivery-volume requirements are suitable.

The transition toward advanced subcutaneous delivery formats is increasingly reflected in commercial product development. In 2025, FDA approved a prefilled syringe version of Argenx’s Vyvgart Hytrulo for at-home self-administration in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Reuters reported that Vyvgart generated USD 2.2 billion in global sales in the prior year, showing that subcutaneous device format can influence access, competitiveness, and earlier-line use for high-value biologics.

Large-volume subcutaneous delivery is emerging as a key engineering focus within biologic administration. A 2025 Springer review states that wearable on-body drug delivery devices enable patient-administered, home-based delivery of biologic volumes exceeding 5–20 mL. This matters because many biologics cannot fit into traditional 1 mL or 2 mL handheld injection limits without high concentration, high viscosity, or painful injection force trade-offs.

The delivery landscape is evolving across handheld autoinjectors, on-body delivery systems, and infusion pumps, each addressing different therapeutic requirements. Autoinjectors support simplified administration with limited user intervention, while on-body systems enable higher-volume biologic delivery while maintaining patient mobility and treatment adherence. Infusion pumps provide precise dosing control but remain less aligned with routine self-managed home administration. As a result, competitive differentiation is shifting from traditional injection formats toward delivery platforms optimized around specific therapeutic and patient needs.

 

Wearable Injectors Are Becoming the Strategic Premium Segment

Wearable subcutaneous devices are gaining relevance because the biologic pipeline is moving faster than conventional injection capacity. On-body devices can deliver moderate to large volumes, often 2–10 mL and in some cases up to 20 mL, over minutes to hours. This positions them between handheld autoinjectors and clinical infusion pumps.

The commercial opportunity extends beyond volume expansion and is increasingly linked to shifts in site of care. Large-volume wearable injectors can enable the transition of selected therapies from infusion centers to home-based or outpatient administration. This approach may reduce infusion-center capacity constraints, improve patient convenience, and support differentiated lifecycle strategies for biologics facing biosimilar competition or market maturation.

Engineering performance remains a key determinant of adoption. High-viscosity biologics require precise control of delivery force, pressure, flow rate, injection duration, tissue backpressure, leakage prevention, and patient comfort. Springer’s review indicates that flow rates exceeding 1 mL/min have been associated with increased discomfort and reduced bioavailability, highlighting the importance of optimized delivery profiles for high-dose biologic administration.

Large-volume feasibility is further supported by advances in autoinjector technologies. A 2023 review identified evidence supporting handheld autoinjectors for volumes up to 2.25 mL, alongside wearable large-volume injectors, syringes, and infusion pumps for higher-dose subcutaneous delivery. These developments maintain the relevance of handheld devices while reinforcing the need for wearable systems as biologic formulations move toward larger-volume administration.

 

Device Design Is Now a Competitive Differentiator

Device design has shifted from simple container selection to a focus on minimizing use errors, enabling digital integration, and aligning with therapy-specific requirements. FDA guidance for pen, jet, and related injectors requires that marketing applications include robust technical and scientific evidence for devices used with drugs or biologics. Manufacturers must demonstrate dose accuracy, functional reliability, validated human factors performance, and proven drug-device compatibility. These are mandatory regulatory expectations and critical determinants of commercial success.

Stevanato Group’s Deora launch reflects the broader transition toward simplified and user-focused delivery systems in diabetes and weight-management therapies. Introduced in June 2026, Deora is a fixed-dose, multi-use pen injector designed for subcutaneous administration, incorporating a pull-push mechanism intended to reduce user complexity and support delivery volumes of up to 0.75 mL.

The shift toward large-volume drug delivery is also accelerating strategic collaborations across the device ecosystem. Datwyler, LTS Device Technologies, and Stevanato Group announced a 2026 collaboration focused on expanding self-administration capabilities for large-volume therapies by integrating container closure systems, wearable delivery technologies, and device manufacturing expertise. These partnerships highlight the increasing importance of system-level integration, where device design, elastomer components, reservoirs, closure technologies, fill-finish processes, and user interfaces collectively determine delivery performance.

 

Market Structure by Device Position

Insulin pens and syringes represent the largest installed base within subcutaneous drug delivery due to the extensive global burden of diabetes management. WHO estimates that 830 million people were living with diabetes worldwide in 2022, with a substantial proportion requiring insulin therapy. In the United States, CDC reported 40.1 million individuals with diabetes in 2023. Despite the emergence of advanced delivery technologies, insulin administration across many regions remains largely dependent on pens and syringes, with NIDDK indicating that these formats continue to account for a major share of insulin use. This creates a structurally stable volume base, although pricing pressures remain significant in emerging markets. Market evolution is increasingly shifting toward connected pen platforms that support dose tracking, treatment adherence, and data-enabled diabetes management.

Autoinjectors are expanding rapidly in chronic biologic therapy. Clinical evidence shows strong patient preference. A randomized study in ulcerative colitis reported 76.9% preference for autoinjectors over prefilled syringes. Ease of use was rated high by 94.5% of patients. This directly impacts adherence and persistence. Autoinjectors are now standard in immunology and migraine biologics. They are also used in osteoporosis and fertility treatments. Their adoption is driven by reduced administration steps and lower training requirements.

Prefilled syringes remain widely used in vaccines and biologics. Regulatory data shows that all 19 FDA-approved vaccine combination products use prefilled syringes. They offer cost efficiency and dosing accuracy. However, they are losing share in chronic self-administration settings. Patient preference and usability advantages are shifting demand toward autoinjectors. Prefilled syringes remain relevant in hospital settings and for therapies requiring clinician oversight.

Wearable on-body injectors represent the fastest evolving segment. These systems enable delivery of volumes above 5 mL and up to 20 mL. This is critical for biologics that cannot be concentrated further due to viscosity constraints. Large-volume delivery allows transition from intravenous infusion to subcutaneous administration. This reduces infusion center burden and improves patient convenience. Engineering challenges remain significant. Flow rate control is critical as rates above 1 mL per minute are associated with increased pain and reduced tolerability. Device reliability and adhesive performance are key determinants of adoption.

Insulin pumps and automated insulin delivery systems represent a high-value segment within diabetes care. These systems provide continuous insulin infusion and integrate with glucose monitoring. Type 1 diabetes affects approximately 9.5 million people globally. This population requires lifelong insulin delivery. Automated systems improve glycemic control and reduce hypoglycemia risk. ADA guidelines recognize these technologies as part of standard diabetes management. Adoption is increasing in developed markets where reimbursement supports advanced diabetes technology.

 

Regional Market Direction

North America remains the most important value market because it combines high diabetes prevalence, GLP-1 adoption, advanced biologics access, FDA-regulated combination products, and reimbursement pathways for self-administered specialty drugs. The U.S. diabetes base of 40.1 million people in 2023 provides durable volume, while FDA approvals such as Vyvgart Hytrulo’s prefilled syringe show how self-administration can expand access in high-value biologics.

Europe is important for biologic lifecycle management and sustainability-led device design. The region’s strong immunology, oncology, and biosimilar markets support demand for autoinjectors, prefilled syringes, and large-volume wearable systems. Environmental pressure will also influence device material choices, reusable formats, and lower-waste designs.

Asia-Pacific is the highest-volume expansion region. India’s 101 million diabetes cases and 136 million prediabetes population create a large access-led device opportunity, while Japan, South Korea, and China support higher-value biologics and device innovation. China’s manufacturing base and GLP-1 demand can also influence global component supply and device cost structure.

 

Competitive Positioning

Competition is split between high-volume injection formats and differentiated biologic delivery platforms. BD, Novo Nordisk device ecosystems, Ypsomed, West Pharmaceutical Services, Stevanato Group, Datwyler, Gerresheimer, SHL Medical, Nemera, Owen Mumford, Enable Injections, LTS Device Technologies, Insulet, Medtronic, Tandem Diabetes Care, and other suppliers compete across pens, prefilled syringes, autoinjectors, wearable injectors, pumps, components, and connected systems.

The strongest companies are not simply device makers. They are platform partners for pharma. Drug developers increasingly need early device selection, fill-finish compatibility, elastomer performance, human-factors testing, digital integration, and scalable manufacturing before launch. This makes contract device development and platform partnerships more strategically important than single-device procurement.

GLP-1 therapy expansion is driving demand for higher manufacturing capacity, while biologic self-administration is increasing the need for more user-centric delivery solutions. Large-volume wearable injectors are accelerating engineering innovation, and connected pens and pumps are expanding the role of digital monitoring and data integration. Companies that can integrate these capabilities across manufacturing, usability, device engineering, and connected care will be better positioned than suppliers competing primarily on unit economics.

 

Analyst Insight

The Subcutaneous Drug Delivery Devices Market is moving from commodity injection hardware toward therapy-linked platform value. Diabetes keeps the market large. GLP-1 therapies make pen and cartridge capacity strategic. Biologics push value toward autoinjectors, prefilled syringes, and large-volume wearable systems. Digital diabetes care moves delivery devices closer to software-enabled disease management.

The most important market indicators are GLP-1 manufacturing capacity, FDA combination-product approvals, biologic switches from IV to SC administration, large-volume device launches, autoinjector preference data, connected-pen adoption, insulin pump integration, human-factors validation, and device-component partnerships.

Market growth will be selective by device type. Syringes and basic pens will remain essential but price-sensitive. Autoinjectors will gain where chronic self-administration and patient preference drive product choice. Wearable injectors will capture premium value where biologic volume, viscosity, and clinic-to-home transition create clear need. Connected pens and pumps will grow where data, dosing accuracy, and diabetes management integration matter.

 

Subcutaneous Drug Delivery Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 34.15 Billion
Revenue Forecast in 2032	USD 55.67 Billion
Overall Growth Rate	CAGR of 7.23% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Device Type, By Delivery Format, By Therapeutic Application, By Drug Type, By Volume Capacity, By End User, By Geography
By Device Type	Conventional Syringes, Insulin Pens, GLP-1 Pen Injectors, Connected Pens, Prefilled Syringes, Autoinjectors, Wearable On-Body Injectors, Insulin Pumps, Automated Insulin Delivery Systems
By Delivery Format	Manual Injection Devices, Pen-Based Delivery Devices, Prefilled Delivery Systems, Wearable Large-Volume Delivery Devices, Connected and Digitally Enabled Delivery Devices
By Therapeutic Application	Diabetes, Obesity and Weight Management, Autoimmune and Inflammatory Diseases, Oncology, Neurology, Rare Diseases, Other Chronic Conditions
By Drug Type	Insulin, GLP-1 Receptor Agonists, Monoclonal Antibodies, Hormonal Therapies, Vaccines, Other Biologics and Specialty Drugs
By Volume Capacity	Small-Volume Delivery Devices, Medium-Volume Delivery Devices, Large-Volume Subcutaneous Delivery Devices
By End User	Home Care Settings, Hospitals and Clinics, Specialty and Ambulatory Care Centers, Pharmaceutical and Biotechnology Companies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising GLP-1 therapy adoption Expanding biologic self-administration Increasing diabetes and obesity burden
Customization Option	Available upon request